Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it ...

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good day, and thank you for standing by.

Myriad Genetics beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $213.3 million, up 11.2% year on year. It was a very strong quarter for the company, ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 ...

In a report released on August 7, Puneet Souda from Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), with a price target of $35.00. Puneet Souda has given ...

Debt Management: Myriad Genetics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.2. This indicates a heavier reliance on borrowed funds, ...

In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Sell rating on Myriad Genetics (MYGN – Research Report), with a price target of $20.00. Rachel Vatnsdal’s rating ...

News Myriad Genetics Hires NIH Scientist-Turned-Biopharma Lawyer as Legal Chief In a statement, Myriad Genetics CEO Paul Diaz praised incoming legal chief Jennifer Fox's experience and expertise ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. Myriad Genetics beat analysts’ revenue expectations ...